US device industry blasts FDA's software guidance
This article was originally published in Clinica
Executive Summary
The US FDA's draft guidance to its agency reviewers for evaluating premarket applications for devices that run with software are overly burdensome, says US industry. In comments submitted to the agency on January 8th, the Health Industry Manufacturers Association said the guidance contains "significant problems" which would lead to increased review times.